These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15582680

  • 1. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period.
    Piper BJ, Meyer JS.
    Pharmacol Biochem Behav; 2004 Dec; 79(4):723-31. PubMed ID: 15582680
    [Abstract] [Full Text] [Related]

  • 2. Repeated MDMA ("Ecstasy") exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter binding.
    Piper BJ, Fraiman JB, Meyer JS.
    Dev Psychobiol; 2005 Sep; 47(2):145-57. PubMed ID: 16136551
    [Abstract] [Full Text] [Related]

  • 3. Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence.
    Meyer JS, Piper BJ, Vancollie VE.
    Ann N Y Acad Sci; 2008 Oct; 1139():151-63. PubMed ID: 18991859
    [Abstract] [Full Text] [Related]

  • 4. Increased responsiveness to MDMA in adult rats treated neonatally with MDMA.
    Piper BJ, Meyer JS.
    Neurotoxicol Teratol; 2006 Oct; 28(1):95-102. PubMed ID: 16271852
    [Abstract] [Full Text] [Related]

  • 5. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
    Wang X, Baumann MH, Xu H, Rothman RB.
    Synapse; 2004 Sep 15; 53(4):240-8. PubMed ID: 15266556
    [Abstract] [Full Text] [Related]

  • 6. Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist.
    Piper BJ, Vu HL, Safain MG, Oliver AJ, Meyer JS.
    J Pharmacol Exp Ther; 2006 May 15; 317(2):838-49. PubMed ID: 16434566
    [Abstract] [Full Text] [Related]

  • 7. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.
    Biezonski DK, Meyer JS.
    J Neurochem; 2010 Feb 15; 112(4):951-62. PubMed ID: 20002520
    [Abstract] [Full Text] [Related]

  • 8. Behavioral and neurochemical consequences of multiple MDMA administrations in the rat: role of individual differences in anxiety-related behavior.
    Ludwig V, Mihov Y, Schwarting RK.
    Behav Brain Res; 2008 May 16; 189(1):52-64. PubMed ID: 18241937
    [Abstract] [Full Text] [Related]

  • 9. Intermittent prenatal MDMA exposure alters physiological but not mood related parameters in adult rat offspring.
    Adori C, Zelena D, Tímár J, Gyarmati Z, Domokos A, Sobor M, Fürst Z, Makara G, Bagdy G.
    Behav Brain Res; 2010 Jan 20; 206(2):299-309. PubMed ID: 19782105
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test.
    Sumnall HR, O'Shea E, Marsden CA, Cole JC.
    Pharmacol Biochem Behav; 2004 Apr 20; 77(4):805-14. PubMed ID: 15099927
    [Abstract] [Full Text] [Related]

  • 12. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.
    J Psychopharmacol; 2006 Mar 20; 20(2):211-25. PubMed ID: 16510479
    [Abstract] [Full Text] [Related]

  • 13. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function.
    Callaghan PD, Owens WA, Javors MA, Sanchez TA, Jones DJ, Irvine RJ, Daws LC.
    J Neurochem; 2007 Feb 20; 100(3):617-27. PubMed ID: 17181558
    [Abstract] [Full Text] [Related]

  • 14. Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density.
    McGregor IS, Clemens KJ, Van der Plasse G, Li KM, Hunt GE, Chen F, Lawrence AJ.
    Neuropsychopharmacology; 2003 Aug 20; 28(8):1472-84. PubMed ID: 12700695
    [Abstract] [Full Text] [Related]

  • 15. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field.
    Mechan AO, Moran PM, Elliott M, Young AJ, Joseph MH, Green R.
    Psychopharmacology (Berl); 2002 Jan 20; 159(2):167-75. PubMed ID: 11862345
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding.
    Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC.
    Eur J Neurosci; 2007 Dec 20; 26(11):3229-36. PubMed ID: 18005064
    [Abstract] [Full Text] [Related]

  • 18. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R, Kerans A, O'Neill B, Harkin A.
    Neuropharmacology; 2006 Jan 20; 50(1):69-80. PubMed ID: 16188283
    [Abstract] [Full Text] [Related]

  • 19. Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression-like behaviour: effects of chronic paroxetine treatment.
    Keck ME, Sartori SB, Welt T, Müller MB, Ohl F, Holsboer F, Landgraf R, Singewald N.
    J Neurochem; 2005 Mar 20; 92(5):1170-9. PubMed ID: 15715667
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.